<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="107505">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01806363</url>
  </required_header>
  <id_info>
    <org_study_id>HTECHL12I_1</org_study_id>
    <nct_id>NCT01806363</nct_id>
  </id_info>
  <brief_title>Pharmacokinetic Interactions and Safety Study of Telmisartan and Chlorthalidone</brief_title>
  <official_title>A Phase I Clinical Trial to Evaluate the Pharmacokinetic Interactions and Safety Between Telmisartan and Chlorthalidone in Healthy Male Volunteers.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>HanAll BioPharma Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>HanAll BioPharma Co., Ltd.</source>
  <oversight_info>
    <authority>Korea: Food and Drug Administration</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Clinical trial to evaluate the pharmacokinetic interactions and safety between telmisartan
      and chlorthalidone.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2012</start_date>
  <completion_date type="Actual">June 2013</completion_date>
  <primary_completion_date type="Actual">June 2013</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Part A : AUC, Cmax of Telmisartan</measure>
    <time_frame>Over a 24-hour sampling period</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Part B : AUC, Cmax of Chlorthalidone</measure>
    <time_frame>Over a 24-hour sampling period</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Part A : Cmin, tmax, CL/F of Telmisartan</measure>
    <time_frame>Over a 24-hour sampling period</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part B : Cmin, tmax, CL/F of Chlorthalidone</measure>
    <time_frame>Over a 24-hour sampling period</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Hypertension</condition>
  <arm_group>
    <arm_group_label>Part A:  Telmisartan, Chlorthalidone + Telmisartan</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>telmisartan 80mg : multiple dose administered orally chlorthalidone 25mg : multiple dose administered orally</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part B: Chlorthalidone, Chlorthalidone + Telmisartan</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>telmisartan 80mg : multiple dose administered orally chlorthalidone 25mg : multiple dose administered orally</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Telmisartan 80mg</intervention_name>
    <arm_group_label>Part A:  Telmisartan, Chlorthalidone + Telmisartan</arm_group_label>
    <arm_group_label>Part B: Chlorthalidone, Chlorthalidone + Telmisartan</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Chlorthalidone 25mg</intervention_name>
    <arm_group_label>Part A:  Telmisartan, Chlorthalidone + Telmisartan</arm_group_label>
    <arm_group_label>Part B: Chlorthalidone, Chlorthalidone + Telmisartan</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Healthy male subjects

          2. Age(yr)between 20 and 50

          3. Signed written informed consent

        Exclusion Criteria:

          1. Known hypersensitivity to investigator product, thiazide, sulphonamide and other
             drugs or additive.

          2. History of any siginificant Sickness, Cardiovascular, Respiratory, Renal, Endocrine,
             Neurological, Psychic, Cancer, Gasstrointestinal, Hematologic.

          3. History of drug and/or alcohol abuse

          4. Over 10 tobaccos a day

          5. Other condition which in the opinion of the investigator preclude enrollment into the
             study
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Young Ran Yoon, Associate Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>KYUNGPOOK NATIONAL UNIVERSITY HOSPITAL, CLINICAL TRIAL CENTER</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Kyungpook national university hospital Clionical center</name>
      <address>
        <city>Daegu</city>
        <state>Gyeongsangbuk-do</state>
        <zip>700-721</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>February 2014</verification_date>
  <lastchanged_date>February 24, 2014</lastchanged_date>
  <firstreceived_date>March 4, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Pharmacokinetics</keyword>
  <keyword>Safety</keyword>
  <keyword>Male</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Chlorthalidone</mesh_term>
    <mesh_term>Telmisartan</mesh_term>
    <mesh_term>Benzoates</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
